Xianliang Li

Dr. Xianliang Li


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

14 June 2022 in Disease Markers
Verified
Journal Article
Open access
PDF file
CDCheng Ding
Cheng Ding
ZYZhangPing Yu
ZhangPing Yu
JZJi-Qiao Zhu
Ji-Qiao Zhu
XLXianliang Li
Xianliang Li
MDMenghua Dai
Menghua Dai
QHQiang He
Qiang He
Pancreatic cancer (PC) is notorious for its parallel morbidity and mortality rates. Recently, necroptosis, a form of programmed cell necrosis, has gained popularity for its role in tumorigenesis and metastasis. In this study, we explored the expression of necroptosis-related genes in PC and normal pancreatic tissues and identified 52 differentially expressed genes (DEGs). The Cox regression analysis was applied to construct the prognostic risk model, which divided patients into high- and low-risk groups. PC patients in the low-risk group showed a significantly better overall survival (OS) than those in the high-risk group. We further validated the prognostic role in ICGC cohort. Further, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Set Enrichment Analysis (GSEA), and tumor microenvironment (TME) analysis were used to explore the underlying mechanisms. Notably, based on the gene signature, we revealed that the risk score was strongly related to the sensitivity of chemotherapy. In conclusion, necroptosis-related genes serve as an important immune mediator, and the risk model could be used to predict the survival and to guide the development of precision drugs for patients with PC.

22 February 2024 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
JZJi-Qiao Zhu
Ji-Qiao Zhu
YZYing Zhu
Ying Zhu
MQMan Qi
Man Qi
YZYe Zeng
Ye Zeng
ZLZhen-Jia Liu
Zhen-Jia Liu
QHQiang He
Qiang He
B cells possess anti-tumor functions mediated by granzyme B, in addition to their role in antigen presentation and antibody production. However, the variations in granzyme B+ B cells between tumor and non-tumor tissues have been largely unexplored. Therefore, we integrated 25 samples from the Gene Expression Omnibus database and analyzed the tumor immune microenvironment. The findings uncovered significant inter- and intra-tumoral heterogeneity. Notably, single-cell data showed higher proportions of granzyme B+ B cells in tumor samples compared to control samples, and these levels were positively associated with disease-free survival. The elevated levels of granzyme B+ B cells in tumor samples resulted from tumor cell chemotaxis through the MIF- (CD74 + CXCR4) signaling pathway. Furthermore, the anti-tumor function of granzyme B+ B cells in tumor samples was adversely affected, potentially providing an explanation for tumor progression. These findings regarding granzyme B+ B cells were further validated in an independent clinic cohort of 40 liver transplant recipients with intrahepatic cholangiocarcinoma. Our study unveils an interaction between granzyme B+ B cells and intrahepatic cholangiocarcinoma, opening up potential avenues for the development of novel therapeutic strategies against this disease.

1 September 2021 in Molecular Immunology
Verified
Journal Article
Closed access
LZLin Zhou
Lin Zhou
HLHan Li
Han Li
XZXin-Xue Zhang
Xin-Xue Zhang
YZYang Zhao
Yang Zhao
JWJing Wang
Jing Wang
XLXianliang Li
Xianliang Li

1 October 2021 in Transplant Immunology
Verified
Journal Article
Closed access
LYLong Yang
Long Yang
JMJun Ma
Jun Ma
QHQiang He
Qiang He
XLXianliang Li
Xianliang Li

1 January 2024 in American Journal of Translational Research
Verified
Journal Article
Closed access
JZJi-Qiao Zhu
Ji-Qiao Zhu
LZLin Zhou
Lin Zhou
JKJian-Tao Kou
Jian-Tao Kou
CDCheng Ding
Cheng Ding
YJYa-Nan Jia
Ya-Nan Jia
XLXianliang Li
Xianliang Li
Background: There is no reliable means to evaluate the immune status of liver transplant recipients. We proposed a novel score model, namely Mingdao immune cell analysis and Mingdao immune score system, to quantify the immunity. Methods: Data from those who underwent a single liver transplant between January 2017 and June 2020 at Beijing Chaoyang Hospital, were collected. In addition, healthy volunteers were also enrolled. The score model was based on the immune cell populations determined by flow cytometry. Results: There were a total of 376 healthy controls with 376 tests and 148 liver transplant recipients with 284 tests in this study. Evaluated by Mingdao immune cell analysis and Mingdao immune score system, the mean scores of healthy controls were near zero suggesting a balanced immune system. In contrast, the mean scores of liver transplant recipients were negative both before and after surgery indicating a compromised immune system. When liver transplant recipients were given a reduced or routine first dose according to their preoperative score, they had similar recovery of liver function. Moreover, liver transplant recipients with increased scores ≥ 5 were associated with elevated aspartate transaminase and alanine amiotransferase. Finally, on multivariate analysis the score model was the only significant independent risk factor for clinical acute rejection (P = 0.021; Odds ratio, 0.913; 95% confidence interval, 0.845-0.987). Conclusion: The novel score model could be used as an indicator to reflect immunity and to regulate immunosuppressants in liver transplant recipients after surgery.